| Title: |
Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B) |
| Authors: |
Sim, SH; Kim, JE; Kim, MH; Park, YH; Kim, JH; Suh, KJ; Koh, SJ; Park, KH; Kang, MJ; Ahn, MS; Lee, KE; Kim, HJ; Ahn, HK; Park, KU; Byun, JH; Park, JH; Lee, GW; Lee, KS; Sohn, J; Jung, KH; Park, IH |
| Contributors: |
105544; Ahn, MS |
| Publication Year: |
2022 |
| Subject Terms: |
Antineoplastic Combined Chemotherapy Protocols; Biosimilar Pharmaceuticals; Breast Neoplasms; Dioxolanes; Female; Humans; Physicians; Receptor; ErbB-2; Trastuzumab; Clinical trial; ctDNA; HER2 positive; Metastatic breast cancer; Trastuzumab biosimilar |
| Description: |
We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma(R), in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
J009609776; http://repository.ajou.ac.kr/handle/201003/24562; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429798 |
| DOI: |
10.1016/j.breast.2022.08.002 |
| Availability: |
http://repository.ajou.ac.kr/handle/201003/24562; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429798; https://doi.org/10.1016/j.breast.2022.08.002 |
| Accession Number: |
edsbas.FEF1FDE2 |
| Database: |
BASE |